ORIX Growth Capital recently completed a financing for Kit Check, the leading provider of automated medications management solutions for hospital pharmacies. Kit Check’s flagship product helps hospitals improve safety and reduce medication inventory in medication kits using RFID and cloud technology to instantly track drugs that were formerly managed manually. The investment will be used to continue expansion for this product, as well as further promote Kit Check’s newest product—Bluesight for Controlled Substances—designed to optimize medication auditing from cabinet to patient and safeguard against drug diversion events at hospitals.
“We seek to invest in transformative businesses able to automate complex workflows head-on in ways that drive measurable value,” said Stasia Carson, Director at ORIX Growth Capital. “Kit Check fits that bill by orchestrating what were time-consuming, manual tasks, while also providing a level of visibility across a hospital’s medication supply chain that was previously unachievable. Traction to date is off the charts, and we’re just glad to play a role in Kit Check’s future successes.”
“ORIX Growth Capital was very happy to deploy capital at Kit Check,” said Bill Bishop, Managing Director of ORIX Growth Capital. “We have been supporting young growing companies for two decades. We admire the strong management teams and investors that have great ideas combined with strong operational efficiencies.”
“Kit Check is transforming the way that hospital pharmacies track and manage their medications by combining more data sets to drive better visibility,” said Kevin MacDonald, co-founder and CEO of Kit Check. “The Bluesight platform gives us a powerful new tool to connect transactional data and identity patterns, and is key to our vision for a comprehensive solution that tracks controlled substances from the receiving dock all the way to the patient. We are grateful that ORIX shares our vision and understands the opportunity that Bluesight offers.”